BIOMAT Database Logo BIOMAT Database Logo

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. 2008

K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
HIV-NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. kiat.r@chula.ac.th

OBJECTIVE TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients. METHODS Patients were randomized to TMC125 800 mg twice a day (bid) (phase II formulation; n=59) or the control PI (n=57), plus two nucleoside reverse transcriptase inhibitors (NRTIs). RESULTS In an unplanned interim analysis, patients receiving TMC125 demonstrated suboptimal virological responses relative to the control PI. Therefore, trial enrolment was stopped prematurely and TMC125 treatment discontinued after a median of 14.3 weeks. In this first-line NNRTI-failure population, baseline NRTI and NNRTI resistance was high and reduced virological responses were observed relative to the control PI. No statistically significant relationship was observed between TMC125 exposure and virological response at week 12. TMC125 was better tolerated than a boosted PI for gastrointestinal-, lipid- and liver-related events. CONCLUSIONS In a PI-naïve population, with baseline NRTI and NNRTI resistance and NRTI recycling, TMC125 was not as effective as first use of a PI. Therefore the use of TMC125 plus NRTIs alone may not be optimal in PI-naïve patients with first-line virological failure on an NNRTI-based regimen. Baseline two-class resistance, rather than pharmacokinetics or other factors, was the most likely reason for suboptimal responses.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor.
February 2007, AIDS alert,
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
November 2009, Current opinion in HIV and AIDS,
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
July 2009, AIDS (London, England),
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
May 2008, AIDS (London, England),
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
April 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
January 2010, Antimicrobial agents and chemotherapy,
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
January 2013, Advances in pharmacology (San Diego, Calif.),
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
May 2019, AIDS (London, England),
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
December 2004, Antimicrobial agents and chemotherapy,
K Ruxrungtham, and R J Pedro, and G H Latiff, and F Conradie, and P Domingo, and S Lupo, and W Pumpradit, and J H Vingerhoets, and M Peeters, and I Peeters, and T N Kakuda, and G De Smedt, and B Woodfall, and
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
December 2008, Expert opinion on pharmacotherapy,
Copied contents to your clipboard!